Last reviewed · How we verify

Placebo to Pentoxifylline oral

UCB Pharma · Phase 3 active Small molecule

Placebo to Pentoxifylline oral is a Rheological agent / Phosphodiesterase inhibitor Small molecule drug developed by UCB Pharma. It is currently in Phase 3 development for Intermittent claudication (peripheral arterial disease), Diabetic angiopathies, Trophic disorders and ischemic ulcers.

Pentoxifylline improves blood flow and reduces blood viscosity by increasing red blood cell flexibility and decreasing platelet aggregation.

Pentoxifylline improves blood flow and reduces blood viscosity by increasing red blood cell flexibility and decreasing platelet aggregation. Used for Intermittent claudication (peripheral arterial disease), Diabetic angiopathies, Trophic disorders and ischemic ulcers.

At a glance

Generic namePlacebo to Pentoxifylline oral
SponsorUCB Pharma
Drug classRheological agent / Phosphodiesterase inhibitor
TargetNon-selective phosphodiesterase inhibitor; multiple targets including adenosine receptors
ModalitySmall molecule
Therapeutic areaCardiovascular / Vascular disease
PhasePhase 3

Mechanism of action

Pentoxifylline is a methylxanthine derivative that acts as a non-selective phosphodiesterase inhibitor and rheological agent. It enhances microcirculation by reducing blood viscosity, improving erythrocyte deformability, and decreasing platelet aggregation and fibrinogen levels. These effects improve oxygen delivery to tissues and reduce inflammatory responses.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo to Pentoxifylline oral

What is Placebo to Pentoxifylline oral?

Placebo to Pentoxifylline oral is a Rheological agent / Phosphodiesterase inhibitor drug developed by UCB Pharma, indicated for Intermittent claudication (peripheral arterial disease), Diabetic angiopathies, Trophic disorders and ischemic ulcers.

How does Placebo to Pentoxifylline oral work?

Pentoxifylline improves blood flow and reduces blood viscosity by increasing red blood cell flexibility and decreasing platelet aggregation.

What is Placebo to Pentoxifylline oral used for?

Placebo to Pentoxifylline oral is indicated for Intermittent claudication (peripheral arterial disease), Diabetic angiopathies, Trophic disorders and ischemic ulcers.

Who makes Placebo to Pentoxifylline oral?

Placebo to Pentoxifylline oral is developed by UCB Pharma (see full UCB Pharma pipeline at /company/ucb).

What drug class is Placebo to Pentoxifylline oral in?

Placebo to Pentoxifylline oral belongs to the Rheological agent / Phosphodiesterase inhibitor class. See all Rheological agent / Phosphodiesterase inhibitor drugs at /class/rheological-agent-phosphodiesterase-inhibitor.

What development phase is Placebo to Pentoxifylline oral in?

Placebo to Pentoxifylline oral is in Phase 3.

What are the side effects of Placebo to Pentoxifylline oral?

Common side effects of Placebo to Pentoxifylline oral include Nausea, Dizziness, Headache, Tremor, Gastrointestinal upset.

What does Placebo to Pentoxifylline oral target?

Placebo to Pentoxifylline oral targets Non-selective phosphodiesterase inhibitor; multiple targets including adenosine receptors and is a Rheological agent / Phosphodiesterase inhibitor.

Related